New drug combo aims to boost bladder cancer remission before surgery
NCT ID NCT06059547
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether adding visugromab to the immunotherapy nivolumab helps shrink muscle-invasive bladder cancer before surgery. The study includes 31 patients who cannot take or refuse standard cisplatin chemotherapy. The main goal is to see how many patients have no cancer left in their bladder after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
visugromab (CTL-002) and nivolumab
What this could lead to
If successful, this combination could offer a new treatment option for muscle-invasive bladder cancer patients who cannot receive standard chemotherapy, potentially increasing the chance of a complete response before surgery.
What could go wrong
This is a small, early-phase (Phase 2) study with only 31 participants. The results may not apply to all patients, and the combination may cause side effects or not improve outcomes compared to existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
A.O.U. Città della Salute e della Scienza di Torino
Torino, 10126, Italy
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, 20133, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica
Roma, 00168, Italy
-
IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University
Milan, 20132, Italy